LGALS3 and cancer: This observation is consistent with previous studies on other glycomimetics targeting galectin‐3, which have also demonstrated that the introduction of hydrophobic moieties can significantly enhance ligand affinity and binding specificity.[17, 19, 55] The findings highlight the potential of selenium‐containing compounds, such as SeDG‐Bn, as a starting point for the development of novel Gal‐3 inhibitors, which could be further optimized to target diseases like cancer and fibrosis, where Gal‐3 overexpression is implicated.